EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-TAO-01(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
India’s CDSCO has conditionally approved allogeneic pooled bone marrow-derived mesenchymal stromal cells (e.g., Stempeucel) for CLI due to Buerger’s disease. Other expanded cellular preparations and autologous bone marrow mononuclear cell (BMMNC) protocols are conducted under strict investigational and ethics-governed clinical trial frameworks.
Pathophysiology & Disease Context:
Buerger’s Disease (Thromboangiitis Obliterans / TAO) is a non-atherosclerotic, segmental inflammatory vasculitis affecting small- and medium-sized arteries and veins of the extremities, leading to severe rest pain, non-healing ischemic ulcers, gangrene, and critical limb ischemia (CLI).
Biological Rationale & Paracrine Action:
Multiple intramuscular micro-injections along the ischemic calf or foot deliver concentrated progenitor cells that secrete potent angiogenic and anti-inflammatory factors (VEGF, bFGF, HGF, Ang-1). This promotes therapeutic angiogenesis, expands collateral microcirculation ("natural bypass"), and downregulates endovascular inflammation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with confirmed thromboangiitis obliterans (Shionoya criteria) exhibiting chronic rest pain (Fontaine Stage III) or ischemic non-healing digital ulcers (Fontaine Stage IV / Rutherford Category 4–6) who are non-candidates for conventional surgical bypass or angioplasty ("no-option" CLI).
Mandatory Pre-Procedure Diagnostics:
Digital Subtraction Angiography (DSA) or CT Peripheral Angiography (confirming segmental occlusion and absence of target run-off vessels), Arterial Doppler (measuring Ankle-Brachial Index [ABI] and Toe-Brachial Index [TBI]), transcutaneous oxygen pressure ($\text{TcPO}_2$), and baseline inflammatory markers.
Strict Safety Exclusion Parameters:
Extensive ascending moist or gas gangrene requiring urgent emergency major amputation; active systemic sepsis; active smoking without commitment to cessation (tobacco cessation is mandatory); or active malignant disease.
Triage Protocol & Multi-Specialty Clearance:
Joint evaluation by a vascular surgeon and interventional radiologist prior to medical visa clearance and travel.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Ischemic Rest Pain Relief: Marked reduction in intractable nocturnal and resting limb pain (VAS pain scores), reducing opioid dependency.
- Ulcer Healing & Epithelialization: Acceleration of wound healing and complete closure of ischemic digital ulcers.
- Collateral Neovascularization: Measurable increases in collateral vascular blush on follow-up digital angiography and Doppler ultrasound.
- Microvascular Perfusion: Objective elevation in transcutaneous oxygen pressure ($\text{TcPO}_2$) and Ankle-Brachial Index (ABI).
- Limb Salvage: Significant reduction in major (above-ankle or above-knee) amputation rates.
- Walking Distance: Improved pain-free claudication distance and mobility.
Documented Procedural Risks & Limits:
- Transient post-injection muscular soreness, local calf swelling, or low-grade pyrexia resolving within 48–72 hours.
- Potential localized wound infection or hematoma at injection tracks.
- No Guaranteed Revascularization: Cellular therapy cannot reopen completely fibrosed primary conduits or salvage non-viable, frankly mummified or gangrenous digits; strict and permanent tobacco cessation is mandatory to sustain collateral vessels.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Hospitals
Delivered in specialized tertiary centers accredited by NABH and JCI with dedicated Limb Salvage and Vascular units.
Vascular Expertise
Led by fellowship-trained peripheral vascular surgeons, interventional radiologists, and certified hyperbaric/wound-care specialists.
CDSCO-Approved Cell Standards
Access to CDSCO-regulated and clinically tested cellular formulations manufactured under international cGMP guidelines.
Ethics Oversight
Supervised by active Institutional Ethics Committees (IEC) registered with the Department of Health Research (DHR) and CDSCO.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior vascular surgeons to examine angiograms, ulcer photographs, and confirm suitability for limb salvage.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport transfers, hospital check-in, priority angiosome mapping, and medical records.
Remote Follow-Up Program
Structured telemedicine consultations at Months 1, 3, 6, and 12, coordinating digital photographic ulcer reviews, ABI metrics, and local wound management.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Gentle Transfers
Private, air-conditioned vehicle pick-up and drop-off accommodating wheelchairs and elevating leg rests to prevent dependent edema and transit trauma.
Accessible Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring step-free access, elevator facilities, walk-in showers, and sanitized dressing areas.
Patient Amenities
Microcirculation-supportive meal planning supervised by clinical dietitians, local SIM card registration, wheelchair loaners, and 24/7 on-call nursing for wound checks.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured inpatient vascular observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Buerger's Disease (Thromboangiitis Obliterans)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Indian Multicenter Phase IV Post-Marketing Surveillance Study of Stempeucel® in Buerger’s Disease
Gupta, P. K., Chullikana, A., Parakh, R., Desai, S., Das, A. K., Gottipamula, S., ... & Stempeucel CLI Study Group. (2021). Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease. Stem Cells Translational Medicine, 10(12), 1602–1613. Clinical Trial Registry Reference: CTRI/2018/02/011839 on CTRI
Multicentric Phase II Dose-Ranging Trial of Allogeneic BM-MSCs in Buerger’s Disease
Gupta, P. K., Chullikana, A., Rao, M. S., Parthiban, B., Murugesan, R., Dutta, S., ... & Majumdar, A. S. (2017). Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II, Prospective, Nonrandomized, Open-Label, Multicentric, Dose-Ranging Study. Stem Cells Translational Medicine, 6(3), 689–699.
Comparative Clinical Trial: Autologous Bone Marrow MSCs vs. Mononuclear Cells in Severe TAO
Lu, D., Chen, B., Liang, Z., Deng, W., Zheng, Y., Shen, F., ... & Han, Z. C. (2011). Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and thromboangiitis obliterans: a double-blind, randomized controlled trial. Diabetes Research and Clinical Practice, 92(1), 26–36.
Clinical Trial on Autologous Adipose-Derived MSCs for Functional Angiogenesis in Buerger’s Disease
Han, J. W., Choi, D., Lee, M. Y., Huh, W., & Yoon, Y. S. (2017). A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial with 2-Year Follow-up Questionnaire Survey for Safety and Efficacy of Adipose-Derived Stem Cells for the Treatment of Buerger's Disease. Stem Cells International, 2017, 5037618.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with directives from the Central Drugs Standard Control Organisation (CDSCO), the Indian Council of Medical Research (ICMR), and the National Medical Commission (NMC), cell therapies for critical limb ischemia and Buerger’s disease are restricted to CDSCO-approved biological formulations or registered, ethics-committee-approved clinical research trials. Biological therapies are adjunctive limb-salvage modalities; they do not guarantee avoidance of amputation in advanced, frankly gangrenous stages and cannot replace emergency revascularization or urgent surgical debridement when indicated. Continued tobacco or nicotine use completely undermines therapeutic angiogenesis.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.